1. EachPod

ReachMD CME - Podcast

ReachMD CME

 ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Health Science & Medicine Medicine
Update frequency
every day
Episodes
499
Years Active
2019 - 2025
Share to:
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

Fri 19 Jul 2024
Real-World Experience With Pacritinib in the US

Real-World Experience With Pacritinib in the US

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/real-world-experience-with-pacritinib-in-the-us/26724/

Primary myelofibrosis is a complex …

Fri 19 Jul 2024
How and When to Manage Ruxolitinib Failure

How and When to Manage Ruxolitinib Failure

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/

Primary myelofibrosis is a complex disea…

Fri 19 Jul 2024
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

Fri 19 Jul 2024
Managing Myelofibrosis-Associated Anemia

Managing Myelofibrosis-Associated Anemia

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/

Primary myelofibrosis is a complex disease…

Fri 19 Jul 2024
Managing Myelofibrosis-Associated Thrombocytopenia

Managing Myelofibrosis-Associated Thrombocytopenia

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/

Primary myelofibrosis is a compl…

Fri 19 Jul 2024
Improving Transfusion Independence With JAK Inhibitor Therapy

Improving Transfusion Independence With JAK Inhibitor Therapy

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/

Primary myelofibrosis…

Fri 19 Jul 2024
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?

Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?

Fri 19 Jul 2024
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/

Primary myelofibrosis is…

Fri 19 Jul 2024
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

Fri 19 Jul 2024
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

Fri 19 Jul 2024
Advancements in GU Cancers: Key Data from AUA 2024

Advancements in GU Cancers: Key Data from AUA 2024

CME credits: 0.50
Valid until: 18-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/advancements-in-gu-cancers-key-data-from-aua-2024/24417/

Despite treatment advances in gen…

Thu 18 Jul 2024
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

Wed 17 Jul 2024
Current Unmet Needs in the Field of Unresectable HCC

Current Unmet Needs in the Field of Unresectable HCC

CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-the-field-of-unresectable-hcc/26329/

This online MinuteCE program p…

Wed 17 Jul 2024
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC

Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC

CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/use-of-ici-combination-regimens-in-patients-with-intermediate-stage-hcc/26333/

This online…

Wed 17 Jul 2024
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

Wed 17 Jul 2024
Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

Wed 17 Jul 2024
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

Wed 17 Jul 2024
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGF Inhibitors

Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGF Inhibitors

Wed 17 Jul 2024
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

Wed 17 Jul 2024
Disclaimer: The podcast and artwork embedded on this page are the property of ReachMD. This content is not affiliated with or endorsed by eachpod.com.